Emergent BioSolutions (EBS) Depreciation & Amortization (CF) (2010 - 2026)

Emergent BioSolutions' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $23.5 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 7.48% year-over-year to $23.5 million; the TTM figure through Mar 2026 stood at $93.9 million (down 11.67% YoY), while the FY2025 annual figure was $95.8 million, down 11.95% from the prior year.
• Depreciation & Amortization (CF) was $23.5 million for Q1 2026 at Emergent BioSolutions, roughly flat from $23.5 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $44.5 million in Q2 2022 to a low of $23.4 million in Q3 2025.
• Historically, Depreciation & Amortization (CF) has averaged $29.2 million across 5 years, with a median of $28.0 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) soared 34.04% in 2022, then fell 26.07% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $35.7 million in 2022, then decreased by 17.09% to $29.6 million in 2023, then decreased by 12.16% to $26.0 million in 2024, then decreased by 9.62% to $23.5 million in 2025, then changed by 0.0% to $23.5 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $23.5 million (Q1 2026), $23.5 million (Q4 2025), and $23.4 million (Q3 2025), per Business Quant data.